Bayer is looking at leading the cardiovascular drug race with its new anti-hypertensive drug moving on to its final stages of clinical trials. The said drug called Finerenone may provide effective and safe benefits as per its mid-stage trials; hence, cardiologists are already looking forward to its progress and completion.
Bayer is looking at leading the cardiovascular drug race with its new anti-hypertensive drug moving on to its final stages of clinical trials. The said drug called Finerenone may provide effective and safe benefits as per its mid-stage trials; hence, cardiologists are already looking forward to its progress and completion.
Share this Article
Recommended